WEST CHESTER, Ohio, April 24 /PRNewswire-FirstCall/ -- AtriCure, Inc. , a medical device company focused on developing, manufacturing and selling innovative surgical devices, will release its financial results for the quarter ended March 31, 2007 on Thursday, May 10, 2007.
AtriCure will also host a Web cast and conference call at 11:00 am EDT on May 10, 2007 to discuss first quarter 2007 results. A live Web cast of the conference call will be available online from the investor relations page of AtriCure’s corporate Web site at http://www.atricure.com. The dial-in numbers are (866) 831-5605 for domestic callers, and (617) 213-8851 for international callers. The reservation number for both is 40584114.
The Web cast will remain available on AtriCure’s Web site through June 10, 2007. A telephonic replay of the call will be available until May 31, 2007. The replay dial-in numbers are (888) 286-8010 for domestic callers and (617) 801-6888 for international callers. Please use reservation code 24348175.
About AtriCure, Inc.
AtriCure, Inc. is a medical device company focused on developing, manufacturing and selling innovative surgical devices designed to create precise lesions, or scars, in soft and cardiac tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure Isolator(TM) bipolar ablation clamps as a treatment alternative during open- heart surgical procedures to create lesions in cardiac, or heart, tissue to block the abnormal electrical impulses that cause atrial fibrillation, or AF, a rapid, irregular quivering of the upper chambers of the heart. Additionally, leading cardiothoracic surgeons have described the AtriCure Isolator(TM) clamps as a promising treatment alternative for patients who may be candidates for sole-therapy minimally invasive procedures. AF affects more than 2.5 million Americans and predisposes them to a five fold increased risk of stroke.
The FDA has cleared the AtriCure Isolator(TM) bipolar ablation system, including the new Isolator(TM) Synergy(TM) ablation clamps, for the ablation, or destruction, of soft tissues in general and non-cardiac related surgical procedures but to date has not cleared or approved the system for cardiac use or for the treatment of AF. The FDA has cleared the AtriCure multifunctional bipolar Pen for the ablation of cardiac tissue and for temporary pacing, sensing, stimulating and recording during the evaluation of cardiac arrhythmias, but the multifunctional bipolar Pen has not been approved for the treatment of AF.
Contacts: AtriCure, Inc.
Julie A. Piton Vice President and Chief Financial Officer (513) 755-4561 jpiton@atricure.com The Ruth Group Nick Laudico (investors) (646) 536-7030 nlaudico@theruthgroup.com Jason Rando (media) (646) 536-7025 jrando@theruthgroup.com
AtriCure, Inc.
CONTACT: Julie A. Piton, Vice President and Chief Financial Officer ofAtriCure, Inc., +1-513-755-4561, jpiton@atricure.com; or Investors, NickLaudico, +1-646-536-7030, nlaudico@theruthgroup.com, or Media, Jason Rando,+1-646-536-7025, jrando@theruthgroup.com, both of The Ruth Group forAtriCure, Inc.
Web site: http://www.atricure.com//
